GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Carna Biosciences Inc (TSE:4572) » Definitions » Cash Ratio

Carna Biosciences (TSE:4572) Cash Ratio : 11.56 (As of Mar. 2024)


View and export this data going back to 2008. Start your Free Trial

What is Carna Biosciences Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Carna Biosciences's Cash Ratio for the quarter that ended in Mar. 2024 was 11.56.

Carna Biosciences has a Cash Ratio of 11.56. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for Carna Biosciences's Cash Ratio or its related term are showing as below:

TSE:4572' s Cash Ratio Range Over the Past 10 Years
Min: 1.87   Med: 7.72   Max: 13.31
Current: 11.56

During the past 13 years, Carna Biosciences's highest Cash Ratio was 13.31. The lowest was 1.87. And the median was 7.72.

TSE:4572's Cash Ratio is ranked better than
84.55% of 1476 companies
in the Biotechnology industry
Industry Median: 3.025 vs TSE:4572: 11.56

Carna Biosciences Cash Ratio Historical Data

The historical data trend for Carna Biosciences's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Carna Biosciences Cash Ratio Chart

Carna Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.66 5.91 4.93 7.74 7.69

Carna Biosciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.48 11.33 12.23 7.69 11.56

Competitive Comparison of Carna Biosciences's Cash Ratio

For the Biotechnology subindustry, Carna Biosciences's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Carna Biosciences's Cash Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Carna Biosciences's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Carna Biosciences's Cash Ratio falls into.



Carna Biosciences Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Carna Biosciences's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash Ratio (A: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=2889.101/375.921
=7.69

Carna Biosciences's Cash Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash Ratio (Q: Mar. 2024 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=3159.233/273.26
=11.56

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Carna Biosciences  (TSE:4572) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Carna Biosciences Cash Ratio Related Terms

Thank you for viewing the detailed overview of Carna Biosciences's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Carna Biosciences (TSE:4572) Business Description

Traded in Other Exchanges
N/A
Address
BMA 3F 1-5-5 Minatojima-Minamimachi, Kobe, JPN, 650-0047
Carna Biosciences, Inc is a Japanese company engaged in drug discovery support business and drug discovery and development business. The company identifies and develops medicines primarily for the treatment of cancer and inflammatory diseases using own innovative kinase drug discovery platform, QuickScout.

Carna Biosciences (TSE:4572) Headlines

No Headlines